[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 30 of about 30
1. Tsuchida K, Yamagata M, Saifuku Y, Ichikawa D, Kanke K, Murohisa T, Tamano M, Iijima M, Nemoto Y, Shimoda W, Komori T, Fukui H, Ichikawa K, Sugaya H, Miyachi K, Fujimori T, Hiraishi H: Successful endoscopic procedures for intraductal papillary neoplasm of the bile duct: a case report. World J Gastroenterol; 2010 Feb 21;16(7):909-13

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful endoscopic procedures for intraductal papillary neoplasm of the bile duct: a case report.
  • Attention has recently been focused on biliary papillary tumors as the novel disease entity intraductal papillary neoplasm of the bile duct (IPNB), which consists of papillary proliferation of dysplastic biliary epithelium.
  • As even benign papillary tumors are considered as premalignant, some investigators recommend aggressive surgical therapy for IPNB, although no guidelines are available to manage this disease.
  • Few reports have described long-term follow-up of patients with benign IPNB without radical resection.
  • [MeSH-major] Common Bile Duct Neoplasms / surgery. Papilloma / surgery. Sphincterotomy, Endoscopic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2004 Mar;28(3):327-38 [15104295.001]
  • [Cites] Am J Gastroenterol. 1989 Apr;84(4):448-9 [2648817.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2003;10(5):390-5 [14598142.001]
  • [Cites] Cancer. 2004 Feb 15;100(4):783-93 [14770435.001]
  • [Cites] Gastrointest Endosc. 2009 Feb;69(2):372-4 [18656860.001]
  • [Cites] Cancer. 1993 Apr 1;71(7):2191-9 [8384065.001]
  • [Cites] J Surg Oncol. 2008 May 1;97(6):508-12 [18314868.001]
  • [Cites] Gastrointest Endosc. 2008 Mar;67(3):574-6 [18207145.001]
  • [Cites] Gastrointest Endosc. 2007 Mar;65(3):519-20, discussion 520 [17210153.001]
  • [Cites] Hepatology. 2006 Nov;44(5):1333-43 [17058219.001]
  • [Cites] Ann Surg. 2006 Aug;244(2):248-53 [16858187.001]
  • [Cites] World J Gastroenterol. 2008 Jul 14;14(26):4234-7 [18636672.001]
  • (PMID = 20143472.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2825340
  •  go-up   go-down


2. Park SM, Shin SM, Seo HE, Kim SH, Kim HS, Park JH, Kim JH, Sohn KR: [A case of sclerosed hemangioma mimicking intrahepatic cholangiocarcinoma]. Korean J Gastroenterol; 2009 Dec;54(6):399-403
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hemangioma is one of the most frequently encountered benign hepatic neoplasm which can develop secondary degeneration.
  • Abdominal ultrasonography revealed GB stone, dilated common bile duct with bile duct stone, and a 4.6 cm sized hyperechoic mass at segment 5 and 6 of the liver.
  • Abdominal dynamic computed tomography demonstrated dilated intrahepatic bile ducts and a 5 x 5 cm sized mass which showed minimally delayed enhancement.
  • We removed common bile duct stone with endoscopic retrograde cholangiopancreatography then decided to undergo right lower segmentectomy of liver due to possibility of cholangiocarcinoma.
  • [MeSH-minor] Aged. Bile Duct Neoplasms / diagnosis. Bile Ducts, Intrahepatic. Cholangiocarcinoma / diagnosis. Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Male. Tomography, X-Ray Computed. Ultrasonography

  • Genetic Alliance. consumer health - Hemangioma.
  • Genetic Alliance. consumer health - Intrahepatic cholangiocarcinoma.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20026896.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


3. Burgos San Juan L: [Cholangiocarcinoma]. Rev Med Chil; 2008 Feb;136(2):240-8
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cholangiocarcinoma is a malignant lesion of the bile duct epithelium.
  • Its etiology is unknown but there are predisposing conditions and environmental risk factors such as primary sclerosing cholangitis, Caroli's disease, bile duct malformations, industrial toxins and parasitic infections.
  • Hilar cholangiocarcinoma must be distinguished from other malignant or benign causes of biliary obstruction.
  • Cholangiocarcinoma of the distal common bile duct must be differentiated from other periampullary tumors and intrahepatic cholangiocarcinoma can be confused with a hepatocellular carcinoma.
  • [MeSH-major] Bile Duct Neoplasms. Bile Ducts, Intrahepatic. Cholangiocarcinoma
  • [MeSH-minor] Humans. Neoplasm Staging / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18483680.001).
  • [ISSN] 0034-9887
  • [Journal-full-title] Revista médica de Chile
  • [ISO-abbreviation] Rev Med Chil
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Chile
  • [Number-of-references] 43
  •  go-up   go-down


Advertisement
4. Leelawat K, Leelawat S, Ratanachu-Ek T, Trubwongchareon S, Wannaprasert J, Tripongkaruna S, Chantawibul S, Tepaksorn P: Circulating hTERT mRNA as a tumor marker in cholangiocarcinoma patients. World J Gastroenterol; 2006 Jul 14;12(26):4195-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The serum of thirty three cholangiocarcinoma patients, forty one benign biliary tract disease patients and ten healthy volunteers were collected and analyzed for the expression of hTERT mRNA by real-time reverse transcriptase-polymerase chain reaction (RT-PCR).
  • RESULTS: hTERT mRNA was detected in 28 of 33 (84.85%) of serum obtained from cholangiocarcinoma patients and 9 of 41 (21.9%) of serum obtained from benign biliary tract disease patients. hTERT mRNA was not detected in any serum obtained from healthy volunteers. on the other hand the common tumor marker, CA19-9 was detected in 20 of 33 (60.6%) of serum obtained from cholangiocarcinoma patients and 8 of 41 (19.5%) of serum obtained from benign biliary tract disease patients.
  • [MeSH-major] Bile Duct Neoplasms / blood. Biomarkers, Tumor / blood. Cholangiocarcinoma / blood. DNA-Binding Proteins / genetics. RNA, Messenger / blood. Telomerase / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bile Ducts, Intrahepatic. Cell Line, Tumor. Female. Gene Expression Regulation, Neoplastic. Humans. Male. Middle Aged. Neoplasm Staging. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg Oncol. 2000 Jan-Feb;7(1):55-66 [10674450.001]
  • [Cites] Clin Cancer Res. 2000 Oct;6(10):3823-6 [11051224.001]
  • [Cites] Nucleic Acids Res. 2001 Aug 15;29(16):3385-93 [11504876.001]
  • [Cites] Ann N Y Acad Sci. 2001 Sep;945:179-88 [11708476.001]
  • [Cites] Clin Chem. 2002 Aug;48(8):1186-93 [12142371.001]
  • [Cites] Expert Rev Mol Diagn. 2005 Nov;5(6):907-16 [16255632.001]
  • [Cites] Oncology. 2004;66(3):167-79 [15218306.001]
  • [Cites] Cancer Res. 1999 Jul 1;59(13):3166-70 [10397260.001]
  • [Cites] Acta Otolaryngol. 2005 Apr;125(4):409-14 [15823813.001]
  • [Cites] Nat Rev Genet. 2005 Aug;6(8):611-22 [16136653.001]
  • [Cites] Asian Pac J Cancer Prev. 2005 Jul-Sep;6(3):276-81 [16235986.001]
  • [Cites] Oncol Rep. 2004 Jan;11(1):245-52 [14654933.001]
  • (PMID = 16830373.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / RNA, Messenger; EC 2.7.7.49 / Telomerase
  • [Other-IDs] NLM/ PMC4087372
  •  go-up   go-down


5. Bloomston M, Kneile J, Butterfield M, Dillhoff M, Muscarella P, Ellison EC, Melvin WS, Croce CM, Pichiorri F, Huebner K, Frankel WL: Coordinate loss of fragile gene expression in pancreatobiliary cancers: correlations among markers and clinical features. Ann Surg Oncol; 2009 Aug;16(8):2331-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Pancreatic, gallbladder and ampullary cancers, normal pancreas, chronic pancreatitis, and benign gallbladder specimens were stained for expression of Fhit, Fhit effector protein Fdxr, Wwox, and other tumor suppressors by immunohistochemistry, and comparisons were made between benign and malignant tissue.
  • RESULTS: Fhit and Wwox were ubiquitously expressed in benign samples and significantly and coordinately reduced in pancreatic, gallbladder, and ampullary cancers.

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2002 Oct 17;21(47):7195-204 [12370809.001]
  • [Cites] Nat Med. 2001 Oct;7(10):1111-7 [11590433.001]
  • [Cites] Cancer Lett. 2003 Sep 25;199(2):131-8 [12969785.001]
  • [Cites] Cancer. 2004 Apr 15;100(8):1605-14 [15073846.001]
  • [Cites] Clin Cancer Res. 2004 Apr 1;10(7):2459-65 [15073125.001]
  • [Cites] Clin Cancer Res. 2004 May 1;10(9):3053-8 [15131042.001]
  • [Cites] Mol Cancer. 2003 Jan 7;2:7 [12537585.001]
  • [Cites] Cancer Res. 1996 Oct 1;56(19):4347-50 [8813121.001]
  • [Cites] Cancer Res. 1998 Apr 15;58(8):1583-7 [9563464.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):5032-7 [9823304.001]
  • [Cites] Cancer Res. 1999 Mar 15;59(6):1308-14 [10096564.001]
  • [Cites] Pathol Int. 2005 Aug;55(8):471-8 [15998374.001]
  • [Cites] Surg Today. 2006;36(1):1-5 [16378185.001]
  • [Cites] Cancer Lett. 2006 Jan 28;232(1):27-36 [16225988.001]
  • [Cites] Hepatogastroenterology. 2006 Jan-Feb;53(67):45-50 [16506374.001]
  • [Cites] Dig Surg. 2006;23(1-2):74-9 [16717472.001]
  • [Cites] Ann Surg Oncol. 2007 Jan;14(1):211-7 [17080236.001]
  • [Cites] Trends Mol Med. 2007 Jan;13(1):12-22 [17142102.001]
  • [Cites] Br J Cancer. 2007 Jan 15;96(1):110-7 [17164758.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Bull Cancer. 2007 Mar;94(3):E8-11 [17371765.001]
  • [Cites] World J Gastroenterol. 2007 Feb 21;13(7):1018-26 [17373735.001]
  • [Cites] Cancer Lett. 2007 May 18;250(1):100-6 [17084965.001]
  • [Cites] J Gastrointest Surg. 2007 May;11(5):578-88 [17468917.001]
  • [Cites] JAMA. 2007 May 2;297(17):1901-8 [17473300.001]
  • [Cites] J Cell Physiol. 2007 Aug;212(2):307-10 [17458891.001]
  • [Cites] Clin Cancer Res. 2007 Oct 15;13(20):6115-21 [17947476.001]
  • [Cites] J Clin Pathol. 2008 Jan;61(1):31-5 [16775119.001]
  • [Cites] Cancer Biol Ther. 2007 Oct;6(10):1592-9 [17912030.001]
  • [Cites] Annu Rev Pathol. 2008;3:157-88 [18039136.001]
  • [Cites] J Biol Chem. 2008 May 16;283(20):13736-44 [18319262.001]
  • [Cites] Cancer Sci. 2008 Jul;99(7):1370-6 [18460020.001]
  • [Cites] Genes Chromosomes Cancer. 2000 Mar;27(3):239-43 [10679912.001]
  • [Cites] Cancer Res. 2001 Jun 15;61(12):4827-36 [11406559.001]
  • [Cites] Mol Carcinog. 2003 Feb;36(2):60-6 [12557261.001]
  • (PMID = 19434452.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA115965; United States / NCI NIH HHS / CA / R01 CA115965-03; United States / NCI NIH HHS / CA / CA133250-01; United States / NCI NIH HHS / CA / R01 CA132453-02; United States / NCI NIH HHS / CA / CA132453; United States / NCI NIH HHS / CA / K12 CA133250-01; United States / NCI NIH HHS / CA / K12 CA133250; United States / NCI NIH HHS / CA / CA132453-02; United States / NCI NIH HHS / CA / CA115965-03; United States / NCI NIH HHS / CA / CA133250; United States / NCI NIH HHS / CA / R01 CA115965; United States / NCI NIH HHS / CA / R01 CA132453
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / Tumor Suppressor Proteins; 0 / fragile histidine triad protein; EC 1.- / Oxidoreductases; EC 1.1.1.- / WWOX protein, human; EC 3.6.- / Acid Anhydride Hydrolases
  • [Other-IDs] NLM/ NIHMS128319; NLM/ PMC2719793
  •  go-up   go-down


6. Hori T, Wagata T, Takemoto K, Shigeta T, Takuwa H, Hata K, Uemoto S, Yokoo N: Spontaneous necrosis of solid gallbladder adenocarcinoma accompanied with pancreaticobiliary maljunction. World J Gastroenterol; 2008 Oct 14;14(38):5933-7
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for gallbladder adenocarcinoma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We were agonized in making the qualitative diagnosis of mass-like lesions of the fundus, such as a benign tumor, cancer, or debris.
  • Amylase levels in the common bile duct and gallbladder were quite high.
  • We therefore undertook radical surgery, including wedge resection of the liver, radical dissection of regional lymph nodes, and resection of the extrahepatic bile duct.
  • [MeSH-minor] Aged. Cholangiography. Cholecystectomy, Laparoscopic. Cholecystitis, Acute / surgery. Fatal Outcome. Gallstones / surgery. Humans. Lymph Node Excision. Magnetic Resonance Imaging. Male. Necrosis. Neoplasm Staging. Tomography, X-Ray Computed. Treatment Outcome. Ultrasonography, Doppler

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Surg Oncol. 2006 Mar;32(2):208-12 [16377119.001]
  • [Cites] Vnitr Lek. 2004 Oct;50(10):781-5 [15633935.001]
  • [Cites] Am J Surg. 2007 Sep;194(3):355-61 [17693282.001]
  • [Cites] J Gastrointest Surg. 2007 Sep;11(9):1188-93 [17712596.001]
  • [Cites] Postgrad Med J. 2000 Feb;76(892):96-8 [10644387.001]
  • [Cites] Hepatogastroenterology. 2000 May-Jun;47(33):631-5 [10919001.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2001;8(1):95-100 [11294297.001]
  • [Cites] Cancer. 2001 Jul 15;92(2):340-8 [11466688.001]
  • [Cites] World J Surg. 2002 Jul;26(7):867-71 [11960212.001]
  • [Cites] Ann Surg Oncol. 2003 May;10(4):447-54 [12734095.001]
  • [Cites] Cancer. 1983 Dec 1;52(11):2086-8 [6627217.001]
  • [Cites] Surg Gastroenterol. 1984;3(2):69-73 [6085899.001]
  • [Cites] Ann Surg. 1992 Apr;215(4):326-31 [1558412.001]
  • [Cites] Eur J Endocrinol. 1994 May;130(5):469-71 [8180674.001]
  • [Cites] Hepatogastroenterology. 1995 Apr;42(2):113-6 [7545638.001]
  • [Cites] Br J Urol. 1995 Oct;76(4):501-3 [7551893.001]
  • [Cites] Surg Endosc. 1997 Dec;11(12):1224-5 [9373301.001]
  • [Cites] Am J Clin Pathol. 1998 Jan;109(1):62-8 [9426519.001]
  • [Cites] Cancer Invest. 1998;16(1):64-5 [9474255.001]
  • [Cites] Cancer. 1998 Aug 1;83(3):423-7 [9690533.001]
  • [Cites] Am Surg. 1998 Aug;64(8):764-7 [9697909.001]
  • [Cites] J Clin Endocrinol Metab. 1953 Aug;13(8):997-1008 [13069604.001]
  • [Cites] World J Gastroenterol. 2006 Apr 28;12(16):2549-55 [16688800.001]
  • (PMID = 18855999.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] China
  • [Number-of-references] 25
  • [Other-IDs] NLM/ PMC2751910
  •  go-up   go-down


7. Khalid K, Alam MK, Al-Shakweer WA, Al-Teimi IN: Granular cell tumour of the ampulla of Vater. J Postgrad Med; 2005 Jan-Mar;51(1):36-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Granular cell tumour (GCT) is a rare soft tissue neoplasm commonly encountered in the head and neck region, skin and subcutaneous tissue.
  • The neoplasm constitutes less than 10% of all benign tumours of the extra-hepatic biliary tree.
  • We report a case of benign GCT involving the ampullary region in a 44-year-old Ethiopian male.
  • [MeSH-major] Ampulla of Vater / pathology. Common Bile Duct Neoplasms / diagnosis. Granular Cell Tumor / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15793336.001).
  • [ISSN] 0022-3859
  • [Journal-full-title] Journal of postgraduate medicine
  • [ISO-abbreviation] J Postgrad Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


8. Uchiyama S, Chijiiwa K, Imamura N, Hiyoshi M, Ohuchida J, Nagano M, Nagaike K, Takahashi N, Akiyama Y: Adenoma of the major duodenal papilla with intraductal extension into the lower common bile duct. J Gastrointest Surg; 2008 Jun;12(6):1146-8
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenoma of the major duodenal papilla with intraductal extension into the lower common bile duct.
  • Although benign and malignant tumors of the major duodenal papilla can be detected endoscopically, definitive diagnosis of such lesions by histologic examination of biopsy specimens is sometimes difficult, especially in cases with intraductal extension into the bile duct or pancreatic duct.
  • We herein report a case of adenoma of the major duodenal papilla showing an intraductal extension into the lower common bile duct that necessitated pylorus-preserving pancreaticoduodenectomy.
  • [MeSH-major] Adenoma / pathology. Ampulla of Vater. Common Bile Duct / pathology. Duodenal Neoplasms / pathology. Neoplasm Invasiveness. Pancreaticoduodenectomy / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17896165.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Agarwal B, Krishna NB, Labundy JL, Safdar R, Akduman EI: EUS and/or EUS-guided FNA in patients with CT and/or magnetic resonance imaging findings of enlarged pancreatic head or dilated pancreatic duct with or without a dilated common bile duct. Gastrointest Endosc; 2008 Aug;68(2):237-42; quiz 334, 335
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EUS and/or EUS-guided FNA in patients with CT and/or magnetic resonance imaging findings of enlarged pancreatic head or dilated pancreatic duct with or without a dilated common bile duct.
  • BACKGROUND: Incidental findings of an enlarged head of pancreas (HOP) or dilated pancreatic duct (PD) with or without a dilated common bile duct (CBD) on CT or magnetic resonance imaging (MRI), in patients without obstructive jaundice, raise suspicion for a pancreatic neoplasm, but their clinical significance has not been established.
  • OBJECTIVE: To determine the prevalence of pancreatic neoplasm in this patient group.
  • (1) The prevalence of pancreatic neoplasms and (2) performance characteristics of EUS-FNA for identifying malignant neoplasm, in this patient group.
  • RESULTS: In 110 study patients, the final diagnosis included adenocarcinoma (n = 7), pancreatic intraepithelial neoplasia (n = 1), neuroendocrine tumor (n = 1), tumor metastasis (n = 1), and benign cyst (n = 3).
  • The accuracy of EUS and EUS-FNA for diagnosing pancreatic neoplasm in these patients was 99.1%, with 88.8% sensitivity, 100% specificity, 99% negative predicative value, and 100% positive predictive value.
  • CONCLUSION: A pancreatic neoplasm is seen in a clinically significant number of patients with "enlarged HOP" or "dilated PD with or without a dilated CBD" but without obstructive jaundice.
  • EUS-FNA seems highly accurate for diagnosing pancreatic neoplasm in these patients.
  • [MeSH-minor] Age Distribution. Aged. Cohort Studies. Common Bile Duct / pathology. Common Bile Duct / ultrasonography. Female. Humans. Immunohistochemistry. Incidence. Magnetic Resonance Imaging / methods. Male. Middle Aged. Pancreatic Ducts / pathology. Pancreatic Ducts / ultrasonography. Pancreatitis / diagnosis. Pancreatitis / epidemiology. Prognosis. Retrospective Studies. Risk Factors. Sensitivity and Specificity. Sex Distribution. Survival Analysis. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Endoscopy. 2010 Jan;42(1):68-72 [20066593.001]
  • (PMID = 18423464.001).
  • [ISSN] 1097-6779
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Kawamoto S, Horton KM, Lawler LP, Hruban RH, Fishman EK: Intraductal papillary mucinous neoplasm of the pancreas: can benign lesions be differentiated from malignant lesions with multidetector CT? Radiographics; 2005 Nov-Dec;25(6):1451-68; discussion 1468-70
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraductal papillary mucinous neoplasm of the pancreas: can benign lesions be differentiated from malignant lesions with multidetector CT?
  • Intraductal papillary mucinous neoplasm (IPMN) of the pancreas is a distinct clinicopathologic entity that is being recognized with increasing frequency.
  • Features predictive of invasive carcinoma in IPMN at CT and other imaging studies include involvement of the main pancreatic duct, marked dilatation of the main pancreatic duct, diffuse or multifocal involvement, the presence of a large mural nodule or solid mass, large size of the mass, and obstruction of the common bile duct.

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] RSNA, 2005.
  • (PMID = 16284127.001).
  • [ISSN] 1527-1323
  • [Journal-full-title] Radiographics : a review publication of the Radiological Society of North America, Inc
  • [ISO-abbreviation] Radiographics
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 43
  •  go-up   go-down


11. Ichimura T, Kondo S, Okamura K, Tanaka E, Hirano S: Total parenchymal pancreatectomy preserving the duodenum, choledochus and spleen for widespread intraductal papillary mucinous neoplasm: report of a case. Hepatogastroenterology; 2010 Jan-Feb;57(97):8-11
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Total parenchymal pancreatectomy preserving the duodenum, choledochus and spleen for widespread intraductal papillary mucinous neoplasm: report of a case.
  • For patients with benign or low malignant diseases of the pancreas, several organ-preserving surgical techniques of pancreatectomy have been presented for localized lesions.
  • We herein report a patient with widespread intraductal papillary mucinous neoplasm treated successfully with total parenchymal pancreatectomy.
  • A 73-year-old man was diagnosed as main duct intraductal papillary mucinous neoplasm.
  • We performed total parenchymal pancreatectomy, an initial surgical procedure in which almost all parenchyma of the pancreas was resected but the duodenum, the common bile duct and the spleen were preserved and no reconstruction was needed.
  • [MeSH-minor] Aged. Common Bile Duct. Duodenum. Humans. Male. Spleen

  • Genetic Alliance. consumer health - Spleen neoplasm.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20422863.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


12. Grobmyer SR, Stasik CN, Draganov P, Hemming AW, Dixon LR, Vogel SB, Hochwald SN: Contemporary results with ampullectomy for 29 "benign" neoplasms of the ampulla. J Am Coll Surg; 2008 Mar;206(3):466-71
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Contemporary results with ampullectomy for 29 "benign" neoplasms of the ampulla.
  • STUDY DESIGN: We retrospectively reviewed our experience with ampullectomy in 29 patients with a preoperative benign histologic diagnosis over 15 years (1991 to 2006).
  • After ampullectomy (median followup=16 months), recurrences were identified in two patients (8%) with benign tumors.
  • [MeSH-major] Adenoma / surgery. Ampulla of Vater. Carcinoma / surgery. Common Bile Duct Neoplasms / pathology. Common Bile Duct Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cohort Studies. Humans. Middle Aged. Neoplasm Invasiveness. Predictive Value of Tests. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18308217.001).
  • [ISSN] 1879-1190
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Zhang J, Wang PJ, Yuan XD: Correlation between CT patterns and pathological classification of intraductal papillary mucinous neoplasm. Eur J Radiol; 2010 Jan;73(1):96-101
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation between CT patterns and pathological classification of intraductal papillary mucinous neoplasm.
  • OBJECTIVE: To examine CT patterns of intraductal papillary mucinous neoplasm (IPMN), analyze their correlation with pathologic classification, and discuss the value of CT in the diagnosis and differential diagnosis of IPMN.
  • (1) simple main pancreatic duct (MPD) dilation type, (2) MPD dilation with pancreatic cystic lesion type, and (3) simple pancreatic cystic lesion type.
  • The 39 IPMN cases were pathologically classified as the benign group and the malignant/borderline group.
  • CT characteristics including the presence or absence of mural nodules, intrafocal partitions, focal size and the degree of MPD and common bile duct (CBD) dilation were analyzed statistically.
  • The benign rate was 92% in patients without intrafocal mural nodules, and 42% in patients with intrafocal mural nodules.
  • The maximum diameter of malignant/borderline lesions was bigger than that of benign ones (p=0.016).
  • There was no significant difference in MPD and CBD diameters between the benign and malignant/borderline groups.

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 19008065.001).
  • [ISSN] 1872-7727
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


14. Zhang J, Wang PJ, Yuan XD, Shao CW, Zhao XH, Xu WG, Dong NX, Wang GL, Shao ZH, Huang ZL, Zhang W: [CT and pathological manifestations of intraductal papillary mucinous neoplasm of pancreas: a comparative study]. Zhonghua Yi Xue Za Zhi; 2008 Apr 8;88(14):943-7
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [CT and pathological manifestations of intraductal papillary mucinous neoplasm of pancreas: a comparative study].
  • OBJECTIVE: To evaluate the diagnostic value of CT in pancreas intraductal papillary mucinous neoplasm (IPMN) by analyzing its CT feature and pathological findings.
  • The CT manifestations were classified into 3 types: simple main pancreatic duct enlargement; main pancreatic duct enlargement combined with pancreatic cystic lesion; and simple pancreatic cystic lesion.
  • The correlation between the CT types and Takada pathological types (main duct type, branch type, and mixed type) was analyzed.
  • All the cases were pathologically classified into benign and malignant/boundary groups.
  • Statistical tests of the difference of CT features (mural nodule, septa, size, caliber of main pancreatic duct and common bile duct) between the 2 groups were performed.
  • RESULTS: The CT type I matched the main duct type, the CT type II mainly matched the branch type and mixed type, and the CT type III matched the branch type (P < 0.001).
  • The probability of benign lesion was 92% with no mural nodule in the lesion, while the probability of benign lesion was only 42% with mural nodule presented (P = 0.003).
  • In terms of the septa, there was no significant difference between benign and malignant lesions (P = 0.793).
  • The size of malignant/boundary lesions exceeded that of benign lesions (P = 0.016).
  • There were no significant difference in calibers of main pancreatic duct and common bile duct between the benign and malignant/ boundary groups.
  • Without considering pathological grouping the caliber of main pancreatic duct exceeded that of the common bile duct in all the cases (P = 0.02).
  • The caliber of main pancreatic duct usually exceeds that of common bile duct in IPMN.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18756963.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


15. Beger HG, Rau BM, Gansauge F, Schwarz M, Siech M, Poch B: Duodenum-preserving total pancreatic head resection for cystic neoplasm: a limited but cancer-preventive procedure. Langenbecks Arch Surg; 2008 Jul;393(4):589-98
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Duodenum-preserving total pancreatic head resection for cystic neoplasm: a limited but cancer-preventive procedure.
  • A malignant transformation of cystic neoplasia is observed in intraductal papillary mucinous tumor (IPMN) lesions in 60% and in mucinous cystic tumor (MCN) lesions in up to 30%.
  • For cystic neoplasia located monocentrically in the pancreatic head and that do not have an association with an invasive pancreatic cancer, the duodenum-preserving total head resection has been used in recent time as a limited surgical procedure.
  • PATIENTS: An indication to duodenum-preserving total pancreatic head resection is considered for patients who do not have clinical signs of an advanced cancer in the lesion and who have main-duct IPMN and monocentric MCN lesions.
  • The long-term outcome is determined by completeness of resection for both -- benign and malignant -- entities.
  • Absence of an advanced pancreatic cancer and completeness of extirpation of the benign tumor determine the long-term outcome.
  • [MeSH-minor] Carcinoma in Situ / pathology. Carcinoma in Situ / surgery. Cell Transformation, Neoplastic / pathology. Common Bile Duct / surgery. Frozen Sections. Humans. Neoplasm Invasiveness. Pancreas / pathology. Prognosis. Suture Techniques. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pediatr Surg. 2006 Dec;41(12):1992-5 [17161189.001]
  • [Cites] Am J Surg. 2001 Feb;181(2):172-6 [11425061.001]
  • [Cites] Am J Surg Pathol. 2004 Aug;28(8):977-87 [15252303.001]
  • [Cites] Ann Surg. 2004 Jun;239(6):788-97; discussion 797-9 [15166958.001]
  • [Cites] Pancreas. 2001 Oct;23(3):309-15 [11590328.001]
  • [Cites] Ann Surg. 2001 Nov;234(5):661-7 [11685030.001]
  • [Cites] Pancreatology. 2006;6(1-2):17-32 [16327281.001]
  • [Cites] Hepatogastroenterology. 1998 Mar-Apr;45(20):533-5 [9638444.001]
  • [Cites] Am J Surg Pathol. 1998 Feb;22(2):163-9 [9500216.001]
  • [Cites] Am J Surg. 2000 Jun;179(6):482-4 [11004335.001]
  • [Cites] Gut. 2007 Aug;56(8):1086-90 [17127707.001]
  • [Cites] Arch Surg. 2003 Feb;138(2):162-8; discussion 168 [12578411.001]
  • [Cites] Arch Surg. 1999 Oct;134(10 ):1131-6 [10522860.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2003;10(2):156-62 [14505149.001]
  • [Cites] Ann Surg. 1997 Oct;226(4):491-8; discussion 498-500 [9351717.001]
  • [Cites] Am J Surg Pathol. 2006 Dec;30(12):1561-9 [17122512.001]
  • [Cites] Oncol Rep. 2003 Jan-Feb;10(1):21-5 [12469138.001]
  • [Cites] Pancreas. 2004 Apr;28(3):241-6 [15084964.001]
  • [Cites] Ann Surg. 2007 Dec;246(6):923-8; discussion 929-31 [18043093.001]
  • [Cites] J Gastrointest Surg. 2003 Jan;7(1):12-8; discussion 18-9 [12559180.001]
  • [Cites] Dig Surg. 2004;21(3):242-5 [15237258.001]
  • [Cites] Arch Surg. 2002 Nov;137(11):1274-8 [12413317.001]
  • [Cites] Hepatogastroenterology. 2001 May-Jun;48(39):879-83 [11462947.001]
  • [Cites] Am J Surg. 1997 Mar;173(3):210-2 [9124628.001]
  • [Cites] J Gastrointest Surg. 2004 Sep-Oct;8(6):713-9 [15358333.001]
  • [Cites] Surgery. 2002 Jul;132(1):80-5 [12110799.001]
  • [Cites] J Clin Gastroenterol. 2003 Mar;36(3):261-5 [12590239.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Nov;2(11):1026-31 [15551256.001]
  • [Cites] Surgery. 2003 Jul;134(1):53-62 [12874583.001]
  • [Cites] J Gastroenterol Hepatol. 2005 Sep;20(9):1379-84 [16105124.001]
  • [Cites] Am J Surg. 1995 Jan;169(1):65-9; discussion 69-70 [7818000.001]
  • [Cites] Int J Gastrointest Cancer. 2002;31(1-3):117-21 [12622422.001]
  • [Cites] Am J Surg Pathol. 2000 Oct;24(10):1372-7 [11023098.001]
  • [Cites] Ann Surg. 2001 Sep;234(3):313-21; discussion 321-2 [11524584.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2002;9(1):76-85 [12021900.001]
  • [Cites] Arch Surg. 2003 Jun;138(6):610-7; discussion 617-8 [12799331.001]
  • [Cites] Ann Surg. 2004 May;239(5):678-85; discussion 685-7 [15082972.001]
  • [Cites] Cancer. 2002 Jan 1;94(1):62-77 [11815961.001]
  • [Cites] Surgery. 2002 May;131(5):577-80 [12019413.001]
  • [Cites] Hepatogastroenterology. 1993 Aug;40(4):356-9 [8406305.001]
  • [Cites] Br J Surg. 2001 Mar;88(3):376-81 [11260102.001]
  • [Cites] Eur J Surg. 2000 Feb;166(2):141-8 [10724492.001]
  • [Cites] Ann Surg. 2004 Mar;239(3):400-8 [15075659.001]
  • [Cites] Gut. 2002 Jun;50(6):861-8 [12010891.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2008;15(2):149-56 [18392707.001]
  • [Cites] Am J Gastroenterol. 1999 Feb;94(2):470-3 [10022648.001]
  • [Cites] Ann Surg. 2007 Oct;246(4):644-51; discussion 651-4 [17893501.001]
  • [Cites] Mod Pathol. 2002 Oct;15(10):1087-95 [12379756.001]
  • [Cites] Chirurg. 1995 Apr;66(4):350-9 [7634946.001]
  • (PMID = 18379818.001).
  • [ISSN] 1435-2451
  • [Journal-full-title] Langenbeck's archives of surgery
  • [ISO-abbreviation] Langenbecks Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


16. Larghi A, Tringali A, Lecca PG, Giordano M, Costamagna G: Management of hilar biliary strictures. Am J Gastroenterol; 2008 Feb;103(2):458-73
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Biliary strictures at the liver hilum are caused by a heterogeneous group of benign and malignant conditions.
  • In the absence of a clear-cut benign etiology, i.e. bile duct damage during surgery, hilar biliary strictures remain a diagnostic and therapeutic challenge for which a multidisciplinary approach is often necessary.
  • For benign post surgical hilar strictures, surgical repair can be difficult and requires specific skills and experience.
  • [MeSH-major] Bile Duct Neoplasms. Hepatic Duct, Common
  • [MeSH-minor] Bile Duct Diseases / diagnosis. Bile Duct Diseases / etiology. Bile Duct Diseases / therapy. Humans. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18028506.001).
  • [ISSN] 0002-9270
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 153
  •  go-up   go-down


17. Moon CM, Bang S, Chung JB, Park SW, Song SY, Yun M, Lee JD: Usefulness of 18F-fluorodeoxyglucose positron emission tomography in differential diagnosis and staging of cholangiocarcinomas. J Gastroenterol Hepatol; 2008 May;23(5):759-65
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this study was to evaluate the clinical usefulness of (18)FDG-PET in differential diagnosis and staging of cholangiocarcinomas according to the intrahepatic, perihilar and common bile duct lesions and to compare with computerized tomography (CT) scan.
  • RESULTS: The overall accuracy of (18)FDG-PET for discriminating malignant diseases of bile duct from benign conditions was slightly higher than that of CT scan (88.9% vs 81.5%).
  • The sensitivity of (18)FDG-PET in perihilar cholangiocarcinoma was lower than the value of intrahepatic and common bile duct cancers (83.3% vs 91.3%, 90.9%); moreover, in cases of perihilar cancer, the sensitivity of (18)FDG-PET was lower than that of CT scans (83.3% vs 91.7%). (18)FDG-PET detected nine distant metastatic lesions not found by other imaging studies and excluded two patients who potentially had resectable condition in other imaging studies from unnecessary laparotomy.
  • CONCLUSION: The clinical usefulness of (18)FDG-PET in differential diagnosis of bile duct cancers is related to the site of primary disease.
  • Although it is a helpful method for differential diagnosis especially in cases of intrahepatic and common bile duct cancers, (18)FDG-PET can not provide confirmative clues in perihilar cholangiocarcinoma. (18)FDG-PET may hold promise in the detection of hidden distant metastasis and can play an additional role in the evaluation of resectability. (18)FDG-PET can be complementary to CT scan in diagnosing and staging of cholangiocarcinoma.
  • [MeSH-major] Bile Duct Neoplasms / pathology. Bile Duct Neoplasms / radionuclide imaging. Bile Ducts, Intrahepatic. Cholangiocarcinoma / pathology. Cholangiocarcinoma / radionuclide imaging. Fluorodeoxyglucose F18. Positron-Emission Tomography. Radiopharmaceuticals
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17931372.001).
  • [ISSN] 1440-1746
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


18. Katsinelos P, Paroutoglou G, Kountouras J, Beltsis A, Papaziogas B, Mimidis K, Zavos C, Dimiropoulos S: Safety and long-term follow-up of endoscopic snare excision of ampullary adenomas. Surg Endosc; 2006 Apr;20(4):608-13

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • If there was no common bile and main pancreatic duct invasion and the appearance suggested a benign lesion, biductal sphincterotomy onto normal duodenal tissue was performed.
  • [MeSH-major] Adenoma / surgery. Ampulla of Vater. Common Bile Duct Neoplasms / surgery. Endoscopy, Digestive System / methods
  • [MeSH-minor] Adult. Aged. Cholangiopancreatography, Endoscopic Retrograde. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Retrospective Studies. Stents. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Hepatobiliary Pancreat Surg. 2004;11(4):232-8 [15368106.001]
  • [Cites] Hepatogastroenterology. 2000 Sep-Oct;47(35):1291-7 [11100335.001]
  • [Cites] Surgery. 1987 Apr;101(4):501-4 [3563897.001]
  • [Cites] Br J Surg. 1997 Jul;84(7):948-51 [9240132.001]
  • [Cites] Cancer. 1989 Jul 1;64(1):161-7 [2471581.001]
  • [Cites] Gastrointest Endosc. 2002 Aug;56(2):239-43 [12145603.001]
  • [Cites] Int J Cancer. 1994 Oct 1;59(1):39-42 [7927901.001]
  • [Cites] Dig Dis. 1998 Sep-Oct;16(5):266-73 [9892786.001]
  • [Cites] Surg Gynecol Obstet. 1989 Nov;169(5):445-8 [2683151.001]
  • [Cites] Endoscopy. 1988 Aug;20 Suppl 1:227-31 [3168951.001]
  • [Cites] Surgery. 1995 Mar;117(3):247-53 [7878528.001]
  • [Cites] Clin Cancer Res. 1997 Jan;3(1):129-33 [9815548.001]
  • [Cites] World J Surg. 2000 Jan;24(1):54-9 [10594204.001]
  • [Cites] Endoscopy. 2003 May;35(5):402-6 [12701011.001]
  • [Cites] Gastrointest Endosc. 2005 Mar;61(3):407-15 [15758912.001]
  • [Cites] Am J Gastroenterol. 1992 Jan;87(1):37-42 [1728122.001]
  • [Cites] Gastrointest Endosc. 2004 Feb;59(2):225-32 [14745396.001]
  • [Cites] Endoscopy. 1995 Jan;27(1):6-11 [7601038.001]
  • [Cites] Arch Surg. 1991 Mar;126(3):353-7 [1998478.001]
  • [Cites] Gastrointest Endosc. 2001 Aug;54(2):202-8 [11474391.001]
  • [Cites] Hum Pathol. 1985 Mar;16(3):305-10 [3972407.001]
  • [Cites] Gastrointest Endosc. 1991 May-Jun;37(3):383-93 [2070995.001]
  • [Cites] Cancer. 1995 Oct 1;76(7):1150-4 [8630891.001]
  • [Cites] Gastrointest Endosc. 2005 Jul;62(1):105-11 [15990827.001]
  • [Cites] Arch Surg. 1999 May;134(5):526-32 [10323425.001]
  • [Cites] Gastrointest Endosc. 1993 Mar-Apr;39(2):127-31 [8495831.001]
  • [Cites] J Gastrointest Surg. 2002 Sep-Oct;6(5):770-5 [12399068.001]
  • (PMID = 16508819.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


19. Espinel Diez J, Vivas Alegre S, Muñoz Núñez F, Domínguez Carbajo A, Villanueva Pavón R, Jorquera Plaza F, Olcoz Goñi JL: [Needle-knife sphincterotomy for biliary access: a prospective study]. Gastroenterol Hepatol; 2005 Aug-Sep;28(7):369-74

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this study was to analyze the results of NNS in patients with an inaccessible common bile duct (difficult cannulation) using standard techniques in endoscopic retrograde cholangiopancreatography and the factors associated with the success of this procedure and complications.
  • MATERIAL AND METHODS: We performed a prospective study of 72 patients who underwent NKS performed by the same endoscopist (J.E.) because of difficult cannulation of the common bile duct between January 1998 and December 2004.
  • The final diagnosis was: choledocholithiasis (31.9%), cancer of the pancreas (16.6%), cholangiocarcinoma (13.8%), benign stenosis (8.3%), dysfunction of the sphincter of Oddi (6.9%), normal (6.9%), and miscellaneous (13.8%).
  • CONCLUSIONS: NKS-PP can be a safe procedure in patients with difficult cannulation of the common bile duct.
  • The presence of biliopancreatic neoplasm is a risk factor for failure to achieve biliary access compared with other diagnoses.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Ampulla of Vater / injuries. Cholangiocarcinoma / diagnosis. Cholangitis / etiology. Choledocholithiasis / diagnosis. Common Bile Duct Neoplasms / diagnosis. Constriction, Pathologic. Female. Hemorrhage / etiology. Humans. Liver Neoplasms / diagnosis. Male. Middle Aged. Pancreatic Neoplasms / diagnosis. Pancreatitis / etiology. Postoperative Complications / etiology. Prospective Studies. Sphincter of Oddi / pathology. Stents

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16137469.001).
  • [ISSN] 0210-5705
  • [Journal-full-title] Gastroenterología y hepatología
  • [ISO-abbreviation] Gastroenterol Hepatol
  • [Language] spa
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 40
  •  go-up   go-down


20. Geraci G, Pisello F, Arnone E, Modica G, Sciumè C: Endoscopic cytology in biliary strictures. Personal experience. G Chir; 2008 Oct;29(10):403-6
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: The differential diagnosis between malignant and benign biliary strictures is the cornerstone of the management of jaundiced patients.
  • The aim of our study is to define the role of cytology of the bile withdrawn during endoscopic retrograde cholangiopancreatography (ERCP), to reach a diagnosis of the nature of biliary stricture.
  • PATIENTS AND METHODS: This retrospective study was conducted on 67 consecutive patients affected of ingravescent obstructive jaundice who underwent ERCP+/-PTE (percutaneous transhepatic endoscopic)+bile withdrawn+stenting.
  • We founded hilar stricture in 21 patients (31.3%), middle third the common duct stricture in 17 (25.3%), and lower third stricture in 28 patients (41.4%).
  • In one patient (2%) the cholangiography did not show any stricture, but we continued with the withdrawn of bile after positioning a naso-biliary drainage.
  • The presence of neoplasm in the pancreato-biliary tract was excluded (absence of malignant cells) in 25 of 40 diagnostic exams (62.5%).
  • During follow-up only 7 of these 25 patients resulted in having a benign disease (true negatives 28%) while the remaining 18 cases were diagnosed with malignant neoplasm of the pancreato-biliary tract (false negatives 72%).
  • Of 25 non-diagnostic samples, 5 (20%) resulted as benign, 20 (80%) as malignant.
  • The statistical analysis by chi-square test allowed us to conclude that bile cytology, if diagnostic, is significantly valid in identifying carcinoma of the pancreato-biliary tract (p<0.05) instead, considering the high rate of non diagnostic samples, its meaning is limited (p=0.09).
  • DISCUSSION: Exfoliative cytology of bile samples obtained during ERCP is easier and less invasive method to determine the diagnosis of biliary strictures, but due to its low sensibility, varying from 6 to 63%, it doesn't appear accurate to establish a definite diagnosis; the stricture dilatation before the withdrawal increases the diagnostic sensibility and accuracy of the cytological exam.
  • CONCLUSION: Bile withdrawn for cytology during ERCP is a safe method with no increasing in patient's morbidity.
  • Bile withdrawn after dilatation of stricture allows improves sensibility and accuracy.
  • [MeSH-major] Bile / cytology. Bile Duct Neoplasms / pathology. Cholangiocarcinoma / pathology. Cholangiopancreatography, Endoscopic Retrograde. Jaundice, Obstructive / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Bile Duct Diseases / pathology. Biopsy, Needle. Chi-Square Distribution. Constriction, Pathologic / diagnosis. Diagnosis, Differential. Drainage / instrumentation. Drainage / methods. Female. Follow-Up Studies. Humans. Male. Middle Aged. Predictive Value of Tests. Retrospective Studies. Sensitivity and Specificity. Stents. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18947461.001).
  • [ISSN] 0391-9005
  • [Journal-full-title] Il Giornale di chirurgia
  • [ISO-abbreviation] G Chir
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


21. Hohmann J, Loddenkemper C, Albrecht T: Assessment of a biliary hamartoma with contrast-enhanced sonography using two different contrast agents. Ultraschall Med; 2009 Apr;30(2):185-8
Hazardous Substances Data Bank. SULFUR HEXAFLUORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Low-MI contrast-enhanced ultrasound (CEUS) with SonoVue (Bracco, Milano, Italy) showed an enhancement pattern which was typical for benign liver lesions while high-MI CEUS with Levovist (Schering, Berlin, Germany) revealed a contrast defect in the liver late phase (4:30 min p. i.) which is typical for a malignant lesion.
  • Histology showed a benign biliary hamartoma and incomplete cirrhosis.
  • Nevertheless biliary duct adenomas are benign lesions with almost the same perfusion properties as normal liver parenchyma.
  • Therefore, while using SonoVue, such a misinterpretation of these very common but in most cases very small and not detectable lesions seems unlikely.
  • [MeSH-major] Adenoma, Bile Duct / ultrasonography. Bile Duct Diseases / ultrasonography. Bile Duct Neoplasms / ultrasonography. Bile Ducts, Intrahepatic / ultrasonography. Contrast Media. Hamartoma / ultrasonography. Phospholipids. Polysaccharides. Sulfur Hexafluoride. Ultrasonography, Doppler, Duplex
  • [MeSH-minor] Biopsy, Fine-Needle. Diagnosis, Differential. Esophageal Neoplasms / pathology. Esophageal Neoplasms / ultrasonography. Humans. Incidental Findings. Liver Neoplasms / pathology. Liver Neoplasms / secondary. Liver Neoplasms / ultrasonography. Male. Middle Aged. Neoplasm Staging. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Bile Duct Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18726842.001).
  • [ISSN] 1438-8782
  • [Journal-full-title] Ultraschall in der Medizin (Stuttgart, Germany : 1980)
  • [ISO-abbreviation] Ultraschall Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Phospholipids; 0 / Polysaccharides; 0 / contrast agent BR1; 127279-08-7 / SHU 508; WS7LR3I1D6 / Sulfur Hexafluoride
  •  go-up   go-down


22. Jarnagin WR, Klimstra DS, Hezel M, Gonen M, Fong Y, Roggin K, Cymes K, DeMatteo RP, D'Angelica M, Blumgart LH, Singh B: Differential cell cycle-regulatory protein expression in biliary tract adenocarcinoma: correlation with anatomic site, pathologic variables, and clinical outcome. J Clin Oncol; 2006 Mar 1;24(7):1152-60
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Tissue microarrays were prepared from paraffin-embedded surgical specimens with triplicate cores of BTA and benign tissue.
  • Tumor sites of origin were intrahepatic cholangiocarcinoma (IH; n = 23), hilar cholangiocarcinoma (Hilar; n = 54), gallbladder (GB; n = 32), and distal bile duct (Distal; n = 19).
  • Aberrant p53 staining and cyclin D1 overexpression were lower in papillary tumors compared with the more common sclerosing tumors.
  • [MeSH-major] Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic. Biomarkers, Tumor / analysis. Cell Cycle Proteins / analysis. Cholangiocarcinoma / pathology. Gallbladder Neoplasms / pathology
  • [MeSH-minor] Aged. Cyclin D1 / analysis. Cyclin-Dependent Kinase Inhibitor p21 / analysis. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Ki-67 Antigen / analysis. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Proliferating Cell Nuclear Antigen / analysis. Proto-Oncogene Proteins c-bcl-2 / analysis. Proto-Oncogene Proteins c-mdm2 / analysis. Survival Analysis. Tumor Suppressor Protein p53 / analysis. Up-Regulation

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16505435.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDKN1A protein, human; 0 / Cell Cycle Proteins; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Ki-67 Antigen; 0 / Proliferating Cell Nuclear Antigen; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53; 0 / p27 antigen; 136601-57-5 / Cyclin D1; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  •  go-up   go-down


23. Carter JT, Grenert JP, Rubenstein L, Stewart L, Way LW: Tumors of the ampulla of vater: histopathologic classification and predictors of survival. J Am Coll Surg; 2008 Aug;207(2):210-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: There were 33 benign (32 adenomas and 1 paraganglioma) and 124 malignant (118 adenocarcinomas and 6 neuroendocrine) tumors.
  • [MeSH-major] Adenocarcinoma / pathology. Ampulla of Vater / pathology. Common Bile Duct Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Female. Follow-Up Studies. Humans. Jaundice, Obstructive / mortality. Jaundice, Obstructive / pathology. Jaundice, Obstructive / surgery. Kaplan-Meier Estimate. Lymphatic Metastasis / pathology. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Retrospective Studies. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18656049.001).
  • [ISSN] 1879-1190
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Ouaïssi M, Sielezneff I, Alves A, Pirro N, Heyries L, Robitail S, Consentino B, Payan MJ, Valleur P, Panis Y, Sastre B: [Long term outcome following 26 surgical ampullectomies]. Ann Chir; 2006 May;131(5):322-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ampullectomy is an alternative to PD for benign ampulloma or, in high-risk patients, for invasive carcinoma.
  • The aim of this study was to report early and long term results of surgical ampullectomy for presumed benign ampullomas.
  • RESULTS: Final pathological examination revealed 15 adenomas, 4 in situ adenocarcinomas, 2 endocrine tumors, and 5 other benign lesions.
  • CONCLUSION: Ampullectomy is a good alternative to PD in case of benign or non-invasive malignant ampullary lesion, including in selected cases of FAP.
  • [MeSH-major] Ampulla of Vater / surgery. Common Bile Duct Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / surgery. Adenoma / surgery. Adenomatous Polyposis Coli / surgery. Adult. Aged. Carcinoma in Situ / surgery. Cause of Death. Common Bile Duct Diseases / surgery. Female. Follow-Up Studies. Granuloma, Plasma Cell / surgery. Humans. Longitudinal Studies. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Retrospective Studies. Somatostatinoma / surgery. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16615931.001).
  • [ISSN] 0003-3944
  • [Journal-full-title] Annales de chirurgie
  • [ISO-abbreviation] Ann Chir
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


25. Barakat O, Rodriguez GC, Raijman I, Allison PM, Nieto J, Ozaki CF, Wood RP, Engler DA: Clinical value of plasma hepatocyte growth factor measurement for the diagnosis of periampullary cancer and prognosis after pancreaticoduodenectomy. J Surg Oncol; 2010 Dec 1;102(7):816-20
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Of the patients enrolled in this pilot study (n = 118), 57 had PAC, 21 had benign pancreatic tumor (BPT), 20 had chronic pancreatitis (CP), and 20 were healthy controls.
  • CONCLUSIONS: Plasma HGF level discriminates well between PAC and other, benign diseases.
  • [MeSH-major] Ampulla of Vater / pathology. Biomarkers, Tumor / blood. Common Bile Duct Neoplasms / blood. Hepatocyte Growth Factor / blood. Pancreaticoduodenectomy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Enzyme-Linked Immunosorbent Assay. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Pilot Projects. Postoperative Period. Prognosis. Retrospective Studies. Survival Rate. Young Adult

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Wiley-Liss, Inc.
  • (PMID = 20812348.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 67256-21-7 / Hepatocyte Growth Factor
  •  go-up   go-down


26. Jung MK, Cho CM, Park SY, Jeon SW, Tak WY, Kweon YO, Kim SK, Choi YH: Endoscopic resection of ampullary neoplasms: a single-center experience. Surg Endosc; 2009 Nov;23(11):2568-74

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A benign adenoma has the potential for malignant transformation.
  • Currently, endoscopic papillectomy with curative intent is increasingly performed for benign papillary tumors.
  • CONCLUSIONS: The findings showed that an endoscopic papillectomy was safe and effective for benign-appearing adenomas with negative biopsy results for a malignancy.
  • [MeSH-major] Adenoma / pathology. Adenoma / surgery. Ampulla of Vater / surgery. Cholangiopancreatography, Endoscopic Retrograde / methods. Common Bile Duct Neoplasms / pathology. Common Bile Duct Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy, Needle. Chi-Square Distribution. Cohort Studies. Female. Follow-Up Studies. Humans. Immunohistochemistry. Male. Middle Aged. Minimally Invasive Surgical Procedures / adverse effects. Minimally Invasive Surgical Procedures / methods. Neoplasm Staging. Pancreaticoduodenectomy / methods. Postoperative Complications / diagnosis. Postoperative Complications / surgery. Probability. Reoperation / methods. Retrospective Studies. Risk Assessment. Sphincterotomy, Endoscopic / adverse effects. Sphincterotomy, Endoscopic / methods. Survival Rate. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endoscopy. 2006 May;38(5):521-5 [16767591.001]
  • [Cites] Surg Endosc. 2006 Apr;20(4):608-13 [16508819.001]
  • [Cites] Gut. 2000 Aug;47(2):251-5 [10896917.001]
  • [Cites] Surgery. 1987 Apr;101(4):501-4 [3563897.001]
  • [Cites] Ann Surg. 1996 Nov;224(5):621-7 [8916877.001]
  • [Cites] Cancer. 1989 Jul 1;64(1):161-7 [2471581.001]
  • [Cites] Gastrointest Endosc. 2005 Sep;62(3):367-70 [16111953.001]
  • [Cites] South Med J. 1989 Jul;82(7):917-20 [2665132.001]
  • [Cites] Surg Gynecol Obstet. 1989 Nov;169(5):445-8 [2683151.001]
  • [Cites] Endoscopy. 1988 Aug;20 Suppl 1:227-31 [3168951.001]
  • [Cites] Surgery. 1995 Mar;117(3):247-53 [7878528.001]
  • [Cites] Cancer. 1981 Aug 1;48(3):799-819 [7248908.001]
  • [Cites] Am Surg. 1990 Apr;56(4):214-7 [2194412.001]
  • [Cites] Ann Surg. 1987 Sep;206(3):358-65 [3632096.001]
  • [Cites] Ann Surg. 2007 Feb;245(2):187-200 [17245171.001]
  • [Cites] Am J Gastroenterol. 1992 Jan;87(1):37-42 [1728122.001]
  • [Cites] Gastrointest Endosc. 2004 Feb;59(2):225-32 [14745396.001]
  • [Cites] Gastrointest Endosc. 2006 May;63(6):789-91 [16650539.001]
  • [Cites] Gastrointest Endosc. 2001 Aug;54(2):202-8 [11474391.001]
  • [Cites] Ann Surg. 1986 Mar;203(3):301-6 [3954483.001]
  • [Cites] Gastrointest Endosc. 1991 May-Jun;37(3):383-93 [2070995.001]
  • [Cites] Gastrointest Endosc. 2004 Nov;60(5):757-64 [15557951.001]
  • [Cites] Gastrointest Endosc. 2006 May;63(6):783-8 [16650538.001]
  • [Cites] Gastrointest Endosc. 1993 Mar-Apr;39(2):127-31 [8495831.001]
  • (PMID = 19360365.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


27. Kawamoto S, Siegelman SS, Hruban RH, Fishman EK: Lymphoplasmacytic sclerosing pancreatitis (autoimmune pancreatitis): evaluation with multidetector CT. Radiographics; 2008 Jan-Feb;28(1):157-70
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is a cause of benign pancreatic disease that can clinically mimic pancreatic cancer.
  • Patients with lymphoplasmacytic sclerosing pancreatitis are often referred for computed tomography (CT) when they are suspected of having a pancreatic or biliary neoplasm; therefore, it is important to search for potential findings suggestive of lymphoplasmacytic sclerosing pancreatitis when typical findings of a pancreatic or biliary neoplasm are not found.
  • Typical CT findings include diffuse or focal enlargement of the pancreas without dilatation of the main pancreatic duct.
  • Thickening and contrast enhancement of the wall of the common bile duct and gallbladder may reflect inflammatory infiltrate and fibrosis associated with lymphoplasmacytic sclerosing pancreatitis.
  • There are several features seen at CT that may help to differentiate lymphoplasmacytic sclerosing pancreatitis from pancreatic cancer, such as diffuse enlargement of the pancreas with minimal peripancreatic stranding in patients with obstructive jaundice, an absence of significant pancreatic atrophy, and an absence of significant main pancreatic duct dilatation.

  • Genetic Alliance. consumer health - Pancreatitis.
  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Pancreatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18203936.001).
  • [ISSN] 1527-1323
  • [Journal-full-title] Radiographics : a review publication of the Radiological Society of North America, Inc
  • [ISO-abbreviation] Radiographics
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 49
  •  go-up   go-down


28. Utispan K, Thuwajit P, Abiko Y, Charngkaew K, Paupairoj A, Chau-in S, Thuwajit C: Gene expression profiling of cholangiocarcinoma-derived fibroblast reveals alterations related to tumor progression and indicates periostin as a poor prognostic marker. Mol Cancer; 2010;9:13
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The common- and unique-expressed genes in Cfs and the promising roles in cancer promotion and progression were determined.
  • Low to no expression of PN was observed in tissues of benign liver disease and hepatocellular carcinoma.
  • [MeSH-major] Bile Duct Neoplasms / genetics. Bile Ducts, Intrahepatic / metabolism. Cell Adhesion Molecules / metabolism. Cholangiocarcinoma / genetics. Cholangiocarcinoma / pathology. Fibroblasts / metabolism. Gene Expression Profiling
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Carcinoma, Hepatocellular / metabolism. Carcinoma, Hepatocellular / pathology. Cell Line, Tumor. Cell Proliferation. Disease Progression. Gene Expression Regulation, Neoplastic. Gene Knockdown Techniques. Humans. Immunohistochemistry. Integrin alpha5 / metabolism. Liver / metabolism. Liver / pathology. Liver Neoplasms / metabolism. Liver Neoplasms / pathology. Neoplasm Invasiveness. Prognosis. Proportional Hazards Models. Reproducibility of Results. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2008 Feb 1;68(3):918-26 [18245495.001]
  • [Cites] Mol Vis. 2007;13:2119-28 [18079685.001]
  • [Cites] Nat Rev Cancer. 2008 Jul;8(7):535-45 [18548086.001]
  • [Cites] J Histochem Cytochem. 2008 Aug;56(8):753-64 [18443362.001]
  • [Cites] Mod Pathol. 2008 Aug;21(8):1044-53 [18487994.001]
  • [Cites] Chin Med J (Engl). 2008 Jul 5;121(13):1220-5 [18710643.001]
  • [Cites] Int J Cancer. 2008 Nov 15;123(10):2229-38 [18777559.001]
  • [Cites] Neuron. 2008 Oct 23;60(2):273-84 [18957219.001]
  • [Cites] Mol Cancer Ther. 2008 Dec;7(12):3842-51 [19056673.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3414-9 [19218429.001]
  • [Cites] Oncol Rep. 2009 Apr;21(4):957-69 [19287994.001]
  • [Cites] Sci Signal. 2009;2(77):ra32 [19567915.001]
  • [Cites] Mol Cell Neurosci. 2000 Nov;16(5):529-41 [11083916.001]
  • [Cites] Cancer. 2001 Aug 15;92(4):843-8 [11550156.001]
  • [Cites] J Urol. 2001 Dec;166(6):2472-83 [11696814.001]
  • [Cites] J Biol Chem. 2002 Apr 5;277(14):12182-9 [11805097.001]
  • [Cites] Neoplasma. 2001;48(6):462-7 [11949838.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11205-10 [12163646.001]
  • [Cites] Cancer Res. 2002 Sep 15;62(18):5358-64 [12235007.001]
  • [Cites] J Biol Chem. 2002 Dec 20;277(51):49820-30 [12393877.001]
  • [Cites] Breast Cancer Res Treat. 2003 Feb;77(3):245-52 [12602924.001]
  • [Cites] Hepatology. 2003 May;37(5):1056-66 [12717386.001]
  • [Cites] J Biol Chem. 2003 Jun 27;278(26):24200-8 [12695522.001]
  • [Cites] J Biol Chem. 2003 Jun 27;278(26):23656-65 [12716911.001]
  • [Cites] Hepatogastroenterology. 2003 Jul-Aug;50(52):924-7 [12845951.001]
  • [Cites] J Neurochem. 2003 Aug;86(3):646-59 [12859678.001]
  • [Cites] Oncogene. 2003 Nov 20;22(52):8487-97 [14627989.001]
  • [Cites] Circulation. 2004 Feb 17;109(6):777-83 [14970115.001]
  • [Cites] Mol Cell Biol. 2004 May;24(9):3992-4003 [15082792.001]
  • [Cites] Trop Med Int Health. 2004 May;9(5):588-94 [15117303.001]
  • [Cites] J Biol Chem. 2004 Jun 4;279(23):24498-504 [15047714.001]
  • [Cites] Cancer Cell. 2004 Jul;6(1):17-32 [15261139.001]
  • [Cites] J Invest Dermatol. 2004 Sep;123(3):592-9 [15304102.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2004 Aug;130(8):943-7 [15313864.001]
  • [Cites] Oncogene. 2004 Sep 23;23(44):7366-77 [15326482.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jun 20;92(13):6161-5 [7541142.001]
  • [Cites] Br J Cancer. 1997;76(5):622-7 [9303361.001]
  • [Cites] Mol Biol Cell. 1999 Feb;10(2):259-70 [9950675.001]
  • [Cites] J Bone Miner Res. 1999 Jul;14(7):1239-49 [10404027.001]
  • [Cites] J Biol Chem. 1999 Aug 13;274(33):23349-57 [10438512.001]
  • [Cites] Nat Rev Cancer. 2004 Nov;4(11):839-49 [15516957.001]
  • [Cites] Parasitology. 2004 Oct;129(Pt 4):455-64 [15521634.001]
  • [Cites] Oncogene. 2004 Dec 2;23(56):9042-51 [15489895.001]
  • [Cites] Int J Mol Med. 2005 Feb;15(2):253-8 [15647840.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2353-63 [15781650.001]
  • [Cites] Carcinogenesis. 2005 May;26(5):908-15 [15731169.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7241-8 [16103075.001]
  • [Cites] Pathol Int. 2005 Nov;55(11):724-31 [16271085.001]
  • [Cites] Expert Opin Ther Targets. 2005 Dec;9(6):1217-33 [16300472.001]
  • [Cites] Semin Liver Dis. 2006 Feb;26(1):42-51 [16496232.001]
  • [Cites] J Hepatol. 2006 Jun;44(6):1066-73 [16480786.001]
  • [Cites] World J Gastroenterol. 2006 Jun 14;12(22):3585-92 [16773716.001]
  • [Cites] Cancer Res. 2006 Jun 15;66(12):6129-38 [16778186.001]
  • [Cites] Pathol Int. 2006 Jul;56(7):381-9 [16792547.001]
  • [Cites] Am J Trop Med Hyg. 2006 Jul;75(1):93-6 [16837714.001]
  • [Cites] Cancer Res. 2006 Jul 15;66(14):6928-35 [16849536.001]
  • [Cites] Br J Cancer. 2006 Nov 20;95(10):1396-403 [17060937.001]
  • [Cites] Oncogene. 2007 Feb 22;26(8):1110-21 [17146433.001]
  • [Cites] Oncogene. 2007 Mar 29;26(14):2082-94 [17043657.001]
  • [Cites] Gastroenterology. 2007 Apr;132(4):1447-64 [17408641.001]
  • [Cites] J Invest Dermatol. 2007 Jun;127(6):1516-23 [17273163.001]
  • [Cites] Breast Cancer Res Treat. 2008 Jul;110(2):273-81 [17899370.001]
  • (PMID = 20096135.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Adhesion Molecules; 0 / Integrin alpha5; 0 / POSTN protein, human
  • [Other-IDs] NLM/ PMC2841583
  •  go-up   go-down


29. Seicean A, Badea R, Stan-Iuga R, Mocan T, Gulei I, Pascu O: Quantitative contrast-enhanced harmonic endoscopic ultrasonography for the discrimination of solid pancreatic masses. Ultraschall Med; 2010 Dec;31(6):571-6
Hazardous Substances Data Bank. SULFUR HEXAFLUORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The histology, based on EUS-FNA or surgery and 9 months of follow-up, was: pancreatic adenocarcinoma (n = 15), pseudotumoral chronic pancreatitis (n = 12), neuroendocrine tumor (n = 1), common bile duct tumor (n = 1), lymph node metastases of gastric cancer (n = 1).
  • This is the first study about CEH-EUS for the quantitative assessment of uptake after contrast injection which has shown that it can aid differentiation between benign and malignant masses but cannot replace EUS-FNA.
  • [MeSH-minor] Aged. Aged, 80 and over. Biopsy. Contrast Media / administration & dosage. Diagnosis, Differential. Female. Humans. Male. Microvessels / ultrasonography. Middle Aged. Neoplasm Staging. Neovascularization, Pathologic / ultrasonography. Pancreatitis, Chronic / pathology. Pancreatitis, Chronic / ultrasonography. Phospholipids. Prospective Studies. Sulfur Hexafluoride

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © Georg Thieme Verlag KG Stuttgart · New York.
  • (PMID = 21080306.001).
  • [ISSN] 1438-8782
  • [Journal-full-title] Ultraschall in der Medizin (Stuttgart, Germany : 1980)
  • [ISO-abbreviation] Ultraschall Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Phospholipids; 0 / contrast agent BR1; WS7LR3I1D6 / Sulfur Hexafluoride
  •  go-up   go-down


30. Katayama M, Funakoshi A, Sumii T, Sanzen N, Sekiguchi K: Laminin gamma2-chain fragment circulating level increases in patients with metastatic pancreatic ductal cell adenocarcinomas. Cancer Lett; 2005 Jul 8;225(1):167-76
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The G2F levels in patients with benign pancreatic tumours (pancreatic cysts and intraductal papillary mucinous tumours) were similar to that in healthy volunteers.
  • On the other hand, the level of the gamma1-chain is a common constituent of several laminin heterotrimers.
  • Interestingly, a significant increase in circulating G2F/G1F ratio was observed in patients with bile duct and gallbladder carcinoma, as well as in those with metastatic pancreatic ductal cell adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / secondary. Biomarkers, Tumor / blood. Carcinoma, Pancreatic Ductal / genetics. Carcinoma, Pancreatic Ductal / pathology. Cell Adhesion Molecules / blood. Laminin / blood. Liver Neoplasms / secondary. Neoplasm Metastasis. Pancreatic Neoplasms / genetics. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Aged. Case-Control Studies. Female. Gastrointestinal Neoplasms / genetics. Gastrointestinal Neoplasms / pathology. Humans. Male. Middle Aged. Neoplasm Invasiveness

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15922869.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Adhesion Molecules; 0 / LAMC2 protein, human; 0 / Laminin; 0 / kalinin
  •  go-up   go-down






Advertisement